Call (541) 334-3350

Call (541) 334-3350

MASK POLICY UPDATE: beginning April 3, 2023    CLICK HERE

RESEARCH CENTER – CLINICAL TRIALS

ACCESS TO THE LATEST
TREATMENTS

Oregon Urology Institute is committed to advancing the standard of care in treating urological disorders and cancers. To achieve this, we are deeply involved in research at our urology clinic. This gives our patients access to experimental procedures and treatments that wouldn’t otherwise be available.

If you’d like to join one of the trials at our urology clinic, your doctor can help determine if you’re a candidate. Qualified candidates will be informed about potential risks and benefits. Our clinical trial participants are carefully monitored, and you can opt out at any time.

CURRENTLY
ENROLLING

Here are trials we’re currently conducting at our urology clinic. Ask your doctor for more information if you’re interested in participating.

PROSTATE CANCER

PSMA-DC

  • Study Type:  Interventional (Clinical Trial)
  • Study Design:
    • Estimated Enrollment: 450 participants
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Masking: None (Open Label)
    • Primary Purpose: Treatment
  • Official Title: An International, Prospective, Open-label, Multicenter, Randomized Phase Ill Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617) versus Observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC)
  • Clinicaltrials.gov link: https://clinicaltrials.gov/study/NCT05939414

PSMAction

  • Study Type:  Interventional (Clinical Trial)
  • Study Design:
    • Estimated Enrollment: 443 participants
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Masking: None (Open Label)
    • Primary Purpose: Treatment
  • Official Title: A Randomised, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients with BRCAm Localised High-Risk Prostate Cancer Receiving Radiotherapy with Androgen Deprivation Therapy (EvoPAR-Prostate02).
  • Clinicaltrials.gov link: https://clinicaltrials.gov/study/NCT06952803

EVOPAR Prostate02

  • Study Type:  Interventional (Clinical Trial)
  • Study Design:
    • Estimated Enrollment: 700 participants
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Masking: Double-Blind
    • Primary Purpose: Treatment
  • Official Title: A Randomised, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients with BRCAm Localised High-Risk Prostate Cancer Receiving Radiotherapy with Androgen Deprivation Therapy (EvoPAR-Prostate02).
  • Clinicaltrials.gov link: https://clinicaltrials.gov/study/NCT06952803

KLK2-PASenger

  • Study Type:  Interventional (Clinical Trial)
  • Study Design:
    • Estimated Enrollment: 800 Participants
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Masking: None (Open Label)
    • Primary Purpose: Treatment
  • Official Title: A Phase 3 Randomized, Open-Label Study of Pasritamig (JNJ-78278343), a T-cell redirecting Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer
  • Clinicaltrials.gov link: https://clinicaltrials.gov/study/NCT07225946

KLK2-comPAS

  • Study Type:  Interventional (Clinical Trial)
  • Study Design:
    • Estimated Enrollment: 1203 Participants
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Masking: None (Open Label)
    • Primary Purpose: Treatment
  • Official Title: A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, + Best Supportive Care Versus Best Supportive Care for Metastatic Castration-resistant Prostate Cancer
  • Clinicaltrials.gov link: https://clinicaltrials.gov/study/NCT07164443

BLADDER CANCER

MoonRISe-3

  • Study Type:  Interventional (Clinical Trial)
  • Study Design:
    • Estimated Enrollment: 220 Participants
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Masking: None (Open Label)
    • Primary Purpose: Treatment
  • Official Title: A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator’s Choice of Intravesical Chemotherapy in Participants with High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG)
  • Clinicaltrials.gov link: https://clinicaltrials.gov/study/NCT06919965

TYR300-202

  • Study Type:  Interventional (Clinical Trial)
  • Study Design:
    • Estimated Enrollment: 90
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Masking: None (Open Label)
    • Primary Purpose: Treatment
  • Official Title: A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of TYRA-300 in Participants with FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)
  • Clinicaltrials.gov link: https://clinicaltrials.gov/study/NCT06995677

OTHER STUDIES

GIAnomics

  • Study Type: Observational (Genetic Testing)
  • Study Design:
    • Estimated Enrollment: 3000 participants
    • Allocation: N/A
    • Intervention Model: N/A
    • Masking: None
    • Primary Purpose: Diagnosis and Risk Assessment
  • Official Title: Genetic Susceptibility and Management of Chronic Disease
  • Link to sponsor page: https://www.genlabus.com/gh101/

PEAK

  • Study Type:  Interventional (Clinical Trial)
  • Study Design:
    • Estimated Enrollment: 92 Participants
    • Allocation: Single Group Assignment
    • Intervention Model: Parallel Assignment
    • Masking: None (Open Label)
    • Primary Purpose: Treatment
  • Official Title: Safety and Effectiveness of the Optilume BPH Catheter System in a Post-Market Study
  • Clinicaltrials.gov link: https://clinicaltrials.gov/study/NCT06312722

VNX001-110

  • Study Type:  Interventional (Clinical Trial)
  • Study Design:
    • Estimated Enrollment: 50 Participants
    • Allocation: Randomized
    • Intervention Model: Single Group Assignment
    • Masking: None (Open Label)
    • Primary Purpose: Treatment
  • Official Title: A Phase 2b, Open Label, Single-Arm, Multi-Center, Multiple Dose, 14-Day Study to Evaluate the Safety, Efficacy, and Frequency of Intravesical Administration of VNX001 in Acute Treatment of Subjects with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) Who Have an Episode of Acute Bladder Pain of Moderate to Severe Intensity.
  • Clinicaltrials.gov link: https://clinicaltrials.gov/study/NCT06394830

ONGOING STUDIES
NOT ENROLLING

PROSTATE CANCER–ATLAS

Study Type: Interventional

Study Design:

  • Allocation: Randomized
  • Actual Enrollment: 1503 Participants
  • Intervention Model: Parallel Assignment
  • Masking: Double Blind (Subject, Investigator)
  • Primary Purpose: Treatment

Official Title: ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy.

For more information on this study, visit clinicaltrials.gov

 

PROSTATE CANCER– TAK-RAD

Study Type:
Interventional

Study Design:

  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Primary Purpose: Treatment

Official Title: A Randomized Controlled Trial of ProstAtak® as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer
For more information on this study, visit clinicaltrials.gov

PROSTATE CANCER–ULYSSES

Study Type:
Interventional

Study Design:
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment

Official Title:
A Randomized Controlled Trial Of AdV-tk + Valacyclovir Administered During Active Surveillance For Newly Diagnosed Prostate Cancer

For more information on this study, visit clinicaltrials.gov

PROSTATE CANCER–PRIMORDIUM

Study Type: Interventional

Study Design:

  • Enrollment Estimate: 412 participants
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Treatment

Official Title: A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (PRIMORDIUM)

For more information on this study, visit clinicaltrials.gov

PROSTATE CANCER–PSMAcare

  • Study Type:  Interventional (Clinical Trial)
  • Study Design:
    • Estimated Enrollment: 120 participants
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Masking: None (Open Label)
    • Primary Purpose: Treatment
  • Official Title: An International Prospective Open-label, Multi-center, Randomized, non-comparative Phase II Study of lutetium (177Lu) vipivotide tetraxetan (AAA617) alone and lutetium (177Lu) vipivotide tetraxetan (AAA617) in combination with Androgen Receptor Pathway Inhibitors in patients with PSMA PET scan positive Castration-Resistant Prostate Cancer
  • Clinicaltrials.gov link: https://clinicaltrials.gov/study/NCT05849298

PROSTATE CANCER–ProVONE

  • Study Type:  Interventional (Clinical Trial)
  • Study Design:
    • Estimated Enrollment: 400 Participants
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Masking: None (Open Label)
    • Primary Purpose: Treatment
  • Official Title: An Open -Label, Multicenter Study of Subjects With Metastatic Castrate-Resistant Prostate Cancer Treated With PROVENGE ® and Boosted With A Single Infusion of Sipuleucel-T to Measure Immune Response.
  • Clinicaltrials.gov link: https://clinicaltrials.gov/study/NCT06134232

PROSTATE CANCER–CLP04-Clarity

  • Study Type:  Interventional (Clinical Trial)
  • Study Design:
    • Estimated Enrollment: 383 Participants
    • Allocation: Randomized
    • Intervention Model: Single Group Assignment
    • Masking: None (Open Label)
    • Primary Purpose: Treatment
  • Official Title: Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy: A Prospective, Single-arm, Multi-center, Blinded-review, Phase 3 Diagnostic Performance Study
  • Clinicaltrials.gov link: https://clinicaltrials.gov/study/NCT06056830

    Bladder Cancer-CORE-008

    • Study Type:  Interventional (Clinical Trial)
    • Study Design:
      • Estimated Enrollment: 325 Participants
      • Allocation: Randomized
      • Intervention Model: Parallel Assignment
      • Masking: None (Open Label)
      • Primary Purpose: Treatment
    • Official Title: A Phase 2, Multi-Arm, Multi-Cohort, Open-label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
    • Clinicaltrials.gov link: https://clinicaltrials.gov/study/NCT06567743

    RESEARCH TEAM

    Bryan Mehlhaff, MD

    DR. BRYAN MEHLHAFF
    Principal Investigator

    Victoria Evans

    VICTORIA EVANS, RN, BSN
    Clinical Research Director

    david dimarco

    DR. DAVID DIMARCO
    Principal Investigator

    Max DiMarco

    MAXIM DIMARCO
    Sr. Clinical Research Coordinator

    Helena McLeod

    HELENA MCLEOD
    Clinical Research Coordinator II

    Sydney DiMarco

    SYDNEY DIMARCO
    Clinical Research Coordinator I

    Gabriel Mancuso

    GABRIEL MANCUSO
    Clinical Research Intern

    Katareanna Jeudy

    KATAREANNA JEUDY
    Research Compliance Specialist II

    Cordell Chase - CTMS Coordinator

    CORDELL CHASE
    CTMS Coordinator

    Claire De La Cruz

    CLAIRE DE LA CRUZ
    Clinical Research Assistant

    Image Coming Soon

    ROBYN SMITH, RN, VA-BC
    PRN Research Nurse

    Krista Snook, RN, BSN

    KRISTA SNOOK, RN, BSN
    PRN Research Nurse

    CONTACT US

    2400 HARTMAN LANE,
    SPRINGFIELD, OR 97477

    PHONE: 541.334.3350
    TOLL FREE: 1.800.246.9925
    FAX: 541.343.3459

    FIND US

    JOIN OUR TEAM